CureVac N.V.

CVAC

NL0015436031

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 15:02:25 14/05/2024 BST			5-day change	1st Jan Change
3.05 ^USD	+2.69%		+1.67%	-27.79%

05-02	CUREVAC : A missed opportunity
04-26	UBS Cuts CureVac Price Target to $14 From $18, Maintains Buy Rating	MT

CUREVAC : UBS raises its recommendation to Buy

January 19, 2023 at 10:24 am

UBS's analyst Eliana Merle raises his rating from Neutral to Buy. The target price has been raised from USD 8 to USD 18.

Latest news about CureVac N.V.

CUREVAC : A missed opportunity	05-02
UBS Cuts CureVac Price Target to $14 From $18, Maintains Buy Rating	04-26	MT
Leerink Partners Downgrades CureVac to Market Perform From Outperform, Sets Price Target at $4	04-25	MT
CureVac N.V. Reports Earnings Results for the Full Year Ended December 31, 2023	04-25	CI
CureVac Begins Early Stage Portion of Investigational Vaccine Trial	04-24	MT
CureVac Hires New Chief Business Officer	04-24	MT
CureVac, GSK Launch Phase 1/2 Trial of Bird Flu Vaccine Candidate	04-24	MT
Transcript : CureVac N.V., Q4 2023 Earnings Call, Apr 24, 2024	04-24
Earnings Flash (CVAC) CUREVAC Posts Q4 Revenue EUR22.6M	04-24	MT
CureVac Appoints Thaminda Ramanayake as New Chief Business Officer, Effective June 1, 2024	04-24	CI
CureVac Announces Start of Combined Phase 1/2 Study in Avian Influenza; Development in Collaboration with GSK	04-24	CI
CureVac N.V. and the University of Texas MD Anderson Cancer Center Enter Strategic Collaboration to Develop Novel Cancer Vaccines	04-16	CI
CureVac Says Phase 2 Interim Data Show Multivalent Flu Vaccine Candidate Boosts Antibody Titers	04-04	MT
CureVac, GSK's Seasonal Flu Shot Shows Efficacy in Phase 1/2 Study	04-04	MT
CureVac, GSK's Seasonal Flu Shot Shows Efficacy in Phase 1/2 Study	04-04	MT
CureVac N.V. Announces Promising Phase 2 Interim Data from Seasonal Influenza Vaccine Development Program in Collaboration with GSK	04-04	CI
CureVac Reports Positive Phase 2 Results for mRNA Covid Vaccines Developed With GSK	01-05	MT
GSK, CureVac Plan Late-stage Study of COVID-19 mRNA Vaccine Candidates	01-05	MT
Dpa-AFX Overview: COMPANIES from 27.12.2023 - 15:15	12-27	DP
Kempen Upgrades CureVac to Buy From Neutral, Price Target is $10	12-22	MT
Global markets live: Fedex, Curevac, Shell, Fedex, Alphabet...	12-20
Sector Update: Health Care Stocks Stronger Late Afternoon	12-19	MT
Top Midday Decliners	12-19	MT
Sector Update: Health Care Stocks Gain in Afternoon Trading	12-19	MT
Sector Update: Health Care	12-19	MT

CureVac AG is a clinical-stage biopharmaceutical company, The Company strives to create transformative medicines to protect and improve peopleâs lives. Fueled by proprietary RNA technology platform combined with two decades of science and manufacturing, The Company is dedicated to creating novel treatments that enable the body to make its own prophylactic and therapeutic drugs.

Sector

Biotechnology & Medical Research

Calendar

21/05/2024 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

CUREVAC : A missed opportunity

May 02, 2024 at 10:42 pm

More Strategies

Ratings for CureVac N.V.

Trading Rating

Investor Rating

ESG Refinitiv

D+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

2.752 EUR

Average target price

9.01 EUR

Spread / Average Target

+227.44%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
CUREVAC N.V.	-27.79%	665M
MODERNA, INC.	+29.31%	48.16B
IQVIA HOLDINGS INC.	-0.58%	41.73B
LONZA GROUP AG	+43.74%	41.03B
CELLTRION, INC.	-5.31%	28.77B
ICON PUBLIC LIMITED COMPANY	+10.93%	25.59B
ALNYLAM PHARMACEUTICALS, INC.	-21.97%	18.96B
BIO-TECHNE CORPORATION	+8.31%	12.92B
MEDPACE HOLDINGS, INC.	+27.13%	12.03B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.20%	11.77B

Other Biotechnology & Medical Research

CureVac N.V.

Equities

CVAC

NL0015436031

Biotechnology & Medical Research

CUREVAC : UBS raises its recommendation to Buy

Latest news about CureVac N.V.

Chart CureVac N.V.

Company Profile

Income Statement Evolution

Analysis / Opinion

Ratings for CureVac N.V.

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research